News >

Positive Topline Results Announced for Cemiplimab in Advanced CSCC

Jason Harris
Published: Wednesday, Dec 13, 2017

Topline results from the pivotal phase II EMPOWER-CSCC 1 study showed that the PD-1 inhibitor cemiplimab (REGN2810) induced an overall response rate (ORR) of 46.3% in patients with advanced cutaneous squamous cell carcinoma (CSCC).

at the 2017 ASH Annual Meeting demonstrating activity with cemiplimab in patients with B-lymphoid malignancies.
  1. Papadopoulos KP, Owonikoko TK, Johnson ML, et al. REGN2810: A fully human anti-PD-1 monoclonal antibody, for patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC)—Initial safety and efficacy from expansion cohorts (ECs) of phase I study. J Clin Oncol 35, 2017 (suppl; abstr 9503).

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Community Practice Connections™: 15th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20202.0
Publication Bottom Border
Border Publication
x